In the 1800s, John D. Rockefeller started refining oil into the world's most valuable fuel. Now, another innovator is creating its own “Rockefeller Moment” with one of the world’s most abundant energy resources: coal.

This is more important than ever right now, because a perfect storm of operational breakthroughs and policy shifts has the potential to directly impact this company’s valuation.

That means investors might not have much longer to lock in the $7.77 share price.

What’s creating this "Rockefeller Moment” for coal?

Using their patented FASForm technology, Frontieras North America can transform coal into high-value commodities like hydrogen, diesel, jet fuel, and fertilizer, without burning it.

They’re targeting a combined $2.1 Trillion in markets where demand for these commodities is virtually unlimited.

Reaching just 2% of the global coal market could mean a Trillion-dollar valuation for Frontieras.

That’s why the "smart money" is already moving. Frontieras has secured a $150M investment commitment from GEM and raised over $20 million from private investors.

But here’s why 2026 is shaping up to be such a historic year for this company:

NASDAQ ticker reserved: Frontieras has officially reserved the "FASF" ticker on the NASDAQ, a major step toward a public listing.
The "Big Beautiful Bill": Under a White House that favors domestic energy, Frontieras is positioned for rapid scale.
Real-World Infrastructure: Frontieras just completed the land purchase for their $850M flagship facility in Mason County, West Virginia.

Frontieras is creating what could be a pivotal moment for the future of energy on the world stage.

Invest at $7.77/share before the window closes on April 9, 2026.

Special Report

3 Stocks Betting Big on Prediction Markets This March Madness

Author: Chris Markoch. Article Published: 3/13/2026.

Key Points

Prediction markets are gaining momentum as March Madness betting could exceed $4 billion in wagers across U.S. sportsbooks.
Robinhood, DraftKings, and Flutter Entertainment are integrating prediction markets into trading and sports betting platforms.
Oversold share prices and expanding adoption of prediction markets could create long-term growth opportunities for investors.
Special Report: Elon Musk's $1 Quadrillion AI IPO

For sports fans, March is one of the best times of the year: the NCAA men’s and women’s basketball tournaments, colloquially known as March Madness. It’s also a peak period for sports betting.

Analysts forecast that up to $4 billion could be wagered at U.S. sportsbooks on this year’s tournament—an opportunity that may interest investors.

Elon's Private AI Empire: The Backdoor Under $100 (Ad)

Elon Musk's AI Everywhere project isn't inside Tesla—it's a private venture with a global network of 150+ facilities embedding autonomous AI into devices everywhere, and Musk believes this could propel Tesla to become the most valuable company ever, worth more than Apple, Microsoft, Nvidia, Amazon, and Google combined. Private ventures like this are usually locked for elites, but I've found a legitimate brokerage backdoor under $100 with no special requirements, just a regular account, and this private play follows the same playbook as PayPal, SpaceX, Tesla, and xAI using Tesla's proven autonomous AI copy-pasted across the world.

See the 3 steps to profit before the summer regulatory shift

Some of the growth expectations are fueled by the expansion of legal wagering into more states. This year, the opportunity is even more intriguing because of the rising popularity of prediction markets. These markets let participants buy and sell contracts on the outcomes of future events, with each contract price reflecting the market’s perceived likelihood of that outcome.

Prediction markets aren’t new, but the internet and blockchain technology have helped address long-standing issues around regulation and trust. In fact, the 2024 presidential election was one of the first times prediction markets entered the national conversation.

The boom has spawned many companies trying to capture this market, but most pure-play prediction-market firms aren’t publicly traded. Still, several established gaming companies are moving into prediction markets, and investors are paying attention.

Robinhood Expands Prediction Markets Inside Its Trading Platform

Robinhood Markets Inc. (NASDAQ: HOOD) has become one of the more prominent names in prediction markets. Its SuperApp increasingly blurs the lines between stock trading, crypto, and prediction markets.

Robinhood provides a leveraged way to gain exposure to prediction-market growth within a diversified, profitable trading platform rather than a single-purpose venue. In its most recent earnings report, the company said prediction-markets revenue is annualizing at $435 million.

That revenue represents about 10% of the record $4.5 billion Robinhood reported for fiscal 2025, up 52% year over year. In the fourth quarter, revenue of $1.28 billion and earnings per share of $0.66 were both at record levels.

Despite those results, HOOD stock is down about 30% in 2026. The share price appears to have formed a bottom and is consolidating ahead of a potential breakout. Analysts’ consensus price target is roughly $120, implying more than 50% upside from recent levels.

DraftKings Brings Prediction Markets Directly Into Sports Betting

Give the people what they want—or at least that seems to be DraftKings’ strategy. DraftKings Inc. (NASDAQ: DKNG) plans to launch “DraftKings Predictions” in 2026, with exclusive integrations across ESPN and NBCUniversal to embed betting and prediction features directly into live sports coverage.

Investors shouldn’t view this as merely playing catch-up. DraftKings is leaning into prediction markets at a time when underlying engagement is accelerating. In its latest earnings report, the company said season-to-date sportsbook hold and net revenue margin have expanded alongside a rising parlay mix, which supports the case for attracting customers who are similar to—but not identical with—traditional sportsbook bettors.

DKNG stock is down about 27% in 2026, tracking a broader decline in consumer discretionary stocks. It appears to have found a bottom, but investors will likely want to see a move back above the 50-day simple moving average (SMA) to confirm a bullish reversal.

FanDuel Owner Flutter Targets Prediction Market Growth

Flutter Entertainment plc (NYSE: FLUT), the parent company of FanDuel, is entering prediction markets from a position of strength. It is one of the world’s leading online sports betting and iGaming operators. In the United States, FanDuel holds roughly 41% of online sportsbook gross gaming revenue and about 28% of iGaming market share, and Flutter views prediction markets as an incremental expansion of its total addressable market rather than a substitute for traditional betting.

In 2025, Flutter generated €16.4 billion ($19.04 billion) in revenue and served nearly 16 million average monthly players across brands such as FanDuel, Sky Bet, PokerStars, and Paddy Power. Group revenue grew 17% last year, with adjusted EBITDA up 21% to €2.85 billion ($3.31 billion), as Flutter leveraged its scale, technology, and its “Flutter Edge” data platform across markets.

The recently launched FanDuel Predicts already offers sports contracts in 18 states and non-sports contracts nationwide. Early engagement is heavily skewed toward sports, and average volume per customer is tracking to management’s expectations. Management plans to invest up to €300 million ($348 million) to build FanDuel Predicts ahead of the 2026 World Cup and the 2026–27 NFL season.

Investors haven’t rewarded the company so far—FLUT stock is down more than 50% in 2026. That said, the shares are showing clear oversold signals, and the consensus price target implies roughly 100% upside over the next 12 months.

Just For You

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments

Authored by Nathan Reiff. Publication Date: 3/12/2026.

Key Points

Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
Special Report: Elon Musk's $1 Quadrillion AI IPO

Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Fortunately, a number of promising treatments have shown significant potential—and with that comes the possibility of substantial sales.

Two smaller biotech companies are enjoying notable share-price momentum thanks to leading oncology medicines. Beyond their therapeutic promise, these drugs may help the firms move toward greater stability and potentially long-term profitability. That said, both companies still face meaningful challenges, making these typical biotech investments high-risk but with the potential for outsized rewards for investors willing to take a chance.

Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle

The rise of the "Useless Class" (Ad)

Famed historian Yuval Noah Harari recently issued a warning that should send a shiver down the spine of every American. He predicts the emergence of a massive new useless class. These aren't just people who are temporarily unemployed. These are people who have become economically irrelevant. As Luke Lango and I just exposed in our recent interview, we have reached the singularity. For the first time in 250 years, intelligence has been decoupled from labor. During America's first 1776 moment, the steam engine replaced muscle. In this new 1776 moment, AI is replacing the human mind.

This is why you see the Magnificent 7 tech giants adding trillions in value while the real economy feels like it's in a death spiral. The divide is widening. On one side: the useless class who cling to old-world skills. On the other: the new aristocracy who own the assets of the technological republic. Luke and I have identified the three specific money moves our research indicates you must make to ensure you stay on the winning side of this divide.

See the three moves to stay on the winning side of AI

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked broader market weakness in early March, surging nearly 37% in a week when the S&P 500 slipped about 1%. That added to IOVA's year-to-date performance, which has more than doubled. Still, with a consensus price target of $8.88, Wall Street sees more upside—that target implies another roughly 71% potential gain from current levels.

The main catalyst for Iovance's rally is its T-cell immunotherapy Amtagvi, approved in the United States in 2024 for certain types of melanoma. Amtagvi has built momentum in sales, and the company expects additional approvals in the EU, U.K., and other jurisdictions. When administered with Proleukin, Iovance's IL-2 immunotherapy, management believes Amtagvi could achieve more than $1 billion in U.S. peak sales.

Amtagvi's potential may extend beyond melanoma. The drug has received FDA Fast Track designation for non-small cell lung cancer and could be investigated for other tumor types.

Iovance also benefited from a Q4 2025 earnings report released in late February that showed narrower-than-expected losses per share and about $5 million in revenue. For the full year, revenue rose roughly 30% year-over-year.

Iovance remains a relatively small biotech (about a $2 billion market cap) and its stock is still viewed as speculative. Analysts are cautious: roughly half of its coverage rates it a Hold or Sell. A key risk is Amtagvi's manufacturing model. Because the therapy is personalized, production is complex and costly, which could constrain margins and slow the path to profitability even as demand grows.

Massive Sales Growth for ImmunityBio's Bladder Cancer Drug

ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance dwarfs that decline—IBRX shares are up nearly 300% in 2026 alone. Analysts have a price target of $13.60, roughly 70% above the stock's current level even after the big run-up.

ImmunityBio's primary growth driver is Anktiva, a therapy for certain bladder cancers. In February, shares climbed after the EU regulator granted conditional marketing authorization—the latest in a series of approvals worldwide.

Anktiva has been driving strong revenue growth: the drug produced $113 million in sales last year, a roughly 700% year-over-year increase. ImmunityBio is also exploring additional indications for Anktiva, which could expand its addressable market.

Despite the dramatic stock appreciation, IBRX remains speculative and risky. The company reported a sizable full-year net loss of $351 million for 2025 as R&D and operating expenses continued to climb. Still, Wall Street sentiment is relatively bullish: six of seven analysts covering the stock rate it a Buy or equivalent.

Both Iovance and ImmunityBio illustrate the upside and downside of small-cap oncology biotech investing—significant commercial potential from breakthrough medicines, paired with execution, manufacturing and financing risks that can keep these stocks volatile.

Thank you for subscribing to TickerReport, where we work around-the-clock
to bring you the latest market-moving news.

This email content is a sponsored email provided by DealMaker, a third-party advertiser of TickerReport and MarketBeat.

This is a paid advertisement for Frontieras's Regulation A offering. Please read the offering circular at https://invest.frontieras.com/

Reservation of the ticker symbol is not a guarantee that we will be listed on the NASDAQ. Listing on the NASDAQ is subject to approvals.

Under Regulation A+, a company has the ability to change its share price by up to 20%, without requalifying the offering with the SEC.

Contact Us | Unsubscribe

Copyright 2006-2026 MarketBeat Media, LLC dba TickerReport. All rights protected.
345 North Reid Place #620, Sioux Falls, South Dakota 57103. United States..